Skip to main content
Erschienen in: Tumor Biology 4/2013

01.08.2013 | Research Article

A common gene variant in PLS3 predicts colon cancer recurrence in women

verfasst von: Joanna Szkandera, Thomas Winder, Michael Stotz, Melanie Weissmueller, Tanja Langsenlehner, Martin Pichler, Hellmut Samonigg, Wilfried Renner, Armin Gerger, Gudrun Absenger

Erschienen in: Tumor Biology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Recent evidence suggests that PLS3 (T-Plastin), an important member of the actin filamentous network, significantly influences cell invasion and metastasis. Germline polymorphisms within the PLS3 gene may impact the gene’s function, resulting in inter-individual differences in tumor recurrence capacity. In the present study, we investigated the association of germline polymorphisms in PLS3 to predict time to recurrence (TTR) in patients with stage II and III colon cancer. A total of 264 patients with histologically confirmed colon cancer were included in this retrospective study. Germline DNA was genotyped for rs871773 C>T, rs757124 C>G, rs1557770 G>T, rs6643869 G>A, and rs2522188 C>T in the PLS3 gene by 5′-exonuclease (TaqMan™) technology. As the PLS3 gene is located on the X chromosome, a gender-specific statistical analysis was performed. In univariate analysis, the minor allele of PLS3 rs871773 C>T was significantly associated with decreased TTR in women (hazard ratio (HR) = 5.02; 95 % confidence interval (CI) = 1.251–20.114; p = 0.023) and remained significantly associated in multivariate analysis (HR = 6.165; 95 % CI = 1.538–24.716; p = 0.010). Female patients carrying the C/T genotype in PLS3 rs871773 showed a median TTR of 69 months. In contrast, female patients with homozygous C/C had a median TTR of 112 months. There were no significant associations between PLS3 rs871773 C>T and TTR in male and between the other polymorphisms and TTR in male or female colon cancer patients. In conclusion, we identified a common gene variant in PLS3 as an independent prognostic marker in female patients with stage II and III colon cancer. Larger prospective trials are warranted to confirm these findings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–8.PubMedCrossRef Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–8.PubMedCrossRef
3.
Zurück zum Zitat Bretscher A. Fimbrin is a cytoskeletal protein that crosslinks F-actin in vitro. Proc Natl Acad Sci U S A. 1981;78:6849–53.PubMedCrossRef Bretscher A. Fimbrin is a cytoskeletal protein that crosslinks F-actin in vitro. Proc Natl Acad Sci U S A. 1981;78:6849–53.PubMedCrossRef
4.
Zurück zum Zitat Gimona M, Djinovic-Carugo K, Kranewitter WJ, Winder SJ. Functional plasticity of CH domains. FEBS Lett. 2002;513:98–106.PubMedCrossRef Gimona M, Djinovic-Carugo K, Kranewitter WJ, Winder SJ. Functional plasticity of CH domains. FEBS Lett. 2002;513:98–106.PubMedCrossRef
5.
Zurück zum Zitat Lin CS, Park T, Chen ZP, Leavitt J. Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. J Biol Chem. 1993;268:2781–92.PubMed Lin CS, Park T, Chen ZP, Leavitt J. Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. J Biol Chem. 1993;268:2781–92.PubMed
6.
Zurück zum Zitat Arpin M, Friederich E, Algrain M, Vernel F, Louvard D. Functional differences between L- and T-plastin isoforms. J Cell Biol. 1994;127:1995–2008.PubMedCrossRef Arpin M, Friederich E, Algrain M, Vernel F, Louvard D. Functional differences between L- and T-plastin isoforms. J Cell Biol. 1994;127:1995–2008.PubMedCrossRef
7.
Zurück zum Zitat Giganti A, Plastino J, Janji B, et al. Actin-filament cross-linking protein T-plastin increases Arp2/3-mediated actin-based movement. J Cell Sci. 2005;118:1255–65.PubMedCrossRef Giganti A, Plastino J, Janji B, et al. Actin-filament cross-linking protein T-plastin increases Arp2/3-mediated actin-based movement. J Cell Sci. 2005;118:1255–65.PubMedCrossRef
8.
Zurück zum Zitat Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett. 1996;397:101–7.PubMedCrossRef Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett. 1996;397:101–7.PubMedCrossRef
9.
Zurück zum Zitat Higuchi Y, Kita K, Nakanishi H, et al. Search for genes involved in UV-resistance in human cells by mRNA differential display: increased transcriptional expression of nucleophosmin and T-plastin genes in association with the resistance. Biochem Biophys Res Commun. 1998;248:597–602.PubMedCrossRef Higuchi Y, Kita K, Nakanishi H, et al. Search for genes involved in UV-resistance in human cells by mRNA differential display: increased transcriptional expression of nucleophosmin and T-plastin genes in association with the resistance. Biochem Biophys Res Commun. 1998;248:597–602.PubMedCrossRef
10.
Zurück zum Zitat Willis ND, Cox TR, Rahman-Casañs SF, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One. 2008;3:e2988.PubMedCrossRef Willis ND, Cox TR, Rahman-Casañs SF, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One. 2008;3:e2988.PubMedCrossRef
11.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.PubMedCrossRef McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–72.PubMedCrossRef
12.
Zurück zum Zitat Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008;36:D820–4.PubMedCrossRef Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008;36:D820–4.PubMedCrossRef
13.
Zurück zum Zitat Gerger A, Langsenlehner U, Renner W, et al. A multigenic approach to predict breast cancer risk. Breast Cancer Res Treat. 2007;104:159–64.PubMedCrossRef Gerger A, Langsenlehner U, Renner W, et al. A multigenic approach to predict breast cancer risk. Breast Cancer Res Treat. 2007;104:159–64.PubMedCrossRef
14.
Zurück zum Zitat dos Remedios CG, Chhabra D, Kekic M, et al. Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev. 2003;83:433–73.PubMed dos Remedios CG, Chhabra D, Kekic M, et al. Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev. 2003;83:433–73.PubMed
15.
Zurück zum Zitat Janmey PA, Chaponnier C. Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol. 1995;7:111–7.PubMedCrossRef Janmey PA, Chaponnier C. Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol. 1995;7:111–7.PubMedCrossRef
16.
Zurück zum Zitat Lin CS, Aebersold RH, Kent SB, Varma M, Leavitt J. Molecular cloning and characterization of plastin, a human leukocyte protein expressed in transformed human fibroblasts. Mol Cell Biol. 1988;8:46596–8. Lin CS, Aebersold RH, Kent SB, Varma M, Leavitt J. Molecular cloning and characterization of plastin, a human leukocyte protein expressed in transformed human fibroblasts. Mol Cell Biol. 1988;8:46596–8.
17.
Zurück zum Zitat Tang N, Gibson H, Germeroth T, Porcu P, Lim HW, Wong HK. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol. 2010;162:463–6.PubMedCrossRef Tang N, Gibson H, Germeroth T, Porcu P, Lim HW, Wong HK. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol. 2010;162:463–6.PubMedCrossRef
Metadaten
Titel
A common gene variant in PLS3 predicts colon cancer recurrence in women
verfasst von
Joanna Szkandera
Thomas Winder
Michael Stotz
Melanie Weissmueller
Tanja Langsenlehner
Martin Pichler
Hellmut Samonigg
Wilfried Renner
Armin Gerger
Gudrun Absenger
Publikationsdatum
01.08.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0754-7

Weitere Artikel der Ausgabe 4/2013

Tumor Biology 4/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.